Dear Alumni, Colleagues, and Friends of the Miller School Family
Following a tumultuous summer punctuated by another surge in COVID-19 cases, the recent increase in vaccination rates in the U.S. fuels our optimism that we may return to a semblance of normalcy sooner rather than later. We recognize, however, that the global pandemic will not subside until close to 70% of the world’s population is fully vaccinated. UHealth and the Miller School of Medicine remain at the forefront of the struggle to combat COVID-19 through the development of rapid diagnostic tests, novel therapeutic modalities and impeccable patient care that has resulted in the lowest mortality rate for COVID-19 in the state.
One of the overarching priorities of the Miller School is to champion fundamental discoveries that can ultimately be translated into clinical interventions to improve the health of humanity. This issue of University of Miami Medicine highlights the success of our researchers in translating their discoveries into clinical interventions by turning their intellectual property into commercial companies. The lead article chronicles the journey from ideation to commercialization.
Henri R. Ford, M.D., M.H.A.
DEAN & CHIEF ACADEMIC OFFICER